Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction

Journal of Experimental Medicine

Volumn 192, Issue 2, 2000, Pages 159-170

  Blackburn, Michael R ^a   Volmer, Jonathan B ^a   Thrasher, Janci L ^a   Zhong, Hongyan ^a   Crosby, Jeff R ^b   Lee, James J ^b   Kellems, Rodney E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Adenosine deaminase; Alveolar macrophage; Asthma; Emphysema; Eosinophil

Indexed keywords

ADENOSINE DEAMINASE;

AIRWAY OBSTRUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CONTROLLED STUDY; EMPHYSEMA; ENZYME DEFICIENCY; EOSINOPHIL; HISTOPATHOLOGY; LUNG ALVEOLUS MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PURINE METABOLISM; TRANSGENIC MOUSE;

ADENOSINE; ADENOSINE DEAMINASE; AIRWAY OBSTRUCTION; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; EOSINOPHILS; IMMUNOGLOBULIN E; INTERLEUKIN-5; LUNG; MICE; MICE, TRANSGENIC; MUCUS; PNEUMONIA; PULMONARY ALVEOLI;

EID: 0034679559     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.192.2.159     Document Type: Article

References (56)

1. Frederiksen, S. 1966. Specificity of adenosine deaminase toward adenosine and 2′-deoxyadenosine analogues. Arch. Biochem. Biophys. 113:383-388.
2. Olah, M.E., and G.L. Stiles. 1995. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol. 35:581-606.
3. Hershfield, M.S., N.M. Kredich, D.R. Ownby, H. Ownby, and R. Buckley. 1979. In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2′-deoxyadenosine in adenosine deaminase-deficient patients. J. Clin. Invest. 63: 807-811.
4. Benveniste, P., W. Zhu, and A. Cohen. 1995. Interference with thymocyte differentiation by an inhibitor of S-adenosylhomocysteine hydrolase. J. Immunol. 155:536-544.
5. Benveniste, P., and A. Cohen. 1995. p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc. Natl. Acad. .Sci. USA. 92:8373-8377.
6. Liu, X., C.N. Kim, J. Yang, R. Jemmerson, and X. Wang. 1996. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 86:147-157.
7. Hershfield, M.S., and B.S. Mitchell. 1995. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In The Metabolic and Molecular Basis of Inherited Disease. 7th ed., Vol. 1. C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, editors. McGraw-Hill, Inc., New York. 1725-1768.
8. Hirschhorn, R. 1999. Immunodeficiency disease due to deficiency of adenosine deaminase. In Primary Immunodeficiency Disease: A Molecular and Genetic Approach. H.D. Ochs, C.I.E. Smith, and J.M. Puck, editors. Oxford University Press, New York. 121-138.
9. Donofrio, J., M.S. Coleman, J.J. Hutton, A. Daoud, B. Lampkin, and J. Dyminski. 1978. Overproduction of adenine deoxynucleosides and deoxynucleotides in adenosine deaminase deficiency with severe combined immunodeficiency disease. J. Clin. Invest. 62:884-887.
10. Kizaki, H., K. Suzuki, T. Tadakuma, and Y. Ishimura. 1990. Adenosine receptor-mediated accumulation of cyclic AMP-induced T-lymphocyte death through internucleosomal DNA cleavage. J. Biol. Chem. 265:5280-5284.
11. Huang, S., S. Apasov, M. Koshiba, and M. Sitkovsky. 1997. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood. 90:1600-1610.
12. Ratech, H., M.A. Greco, G. Gallo, D.L. Rimoin, H. Kamino, and R. Hirschhorn. 1985. Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations. Am. J. Pathol. 120:157-169.
13. Bollinger, M.E., F.X. Arredondo-Vega, I. Santisteban, K. Schwarz, M.S. Hershfield, and H.M. Lederman. 1996. Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. N. Engl. J. Med. 334:1367-1371.
14. Hirschhorn, R., P.S. Paageorgiou, H.H. Kesarwala, and L.T. Taft. 1980. Amelioration of neurologic abnormalities after "enzyme replacement" in adenosine deaminase deficiency. N. Engl. J. Med. 303:377-380.
15. Blackburn, M.R., S.K. Datta, and R.E. Kellems. 1998. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J. Biol. Chem. 273:5093-5100.
16. Wakamiya, M., M.R. Blackburn, R. Jurecic, M.J. McArthur, R.S. Geske, J. Cartwright, Jr., K. Mitani, S. Vaishnav, J.W. Belmont, R.E. Kellems, et al. 1995. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc. Natl. Acad. Sci. USA. 92: 3673-3677.
17. Migehielsen, A.A., M.L. Breuer, M.A. van Roon, H. te Riele, C. Zurcher, F. Ossendorp, S. Toutain, M.S. Hershfield, A. Berns, and D. Valerio. 1995. Adenosine-deaminase-deficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death. Nat. Genet. 10:279-287.
18. Blackburn, M.R., M. Wakamiya, C.T. Caskey, and R.E. Kellems. 1995. Tissue-specific rescue suggests that placental adenosine deaminase is important for fetal development in mice. J. Biol. Chem. 270:23891-23894.
19. Blackburn, M.R., S.K. Datta, M. Wakamiya, B.S. Vartabedian, and R.E. Kellems. 1996. Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. J. Biol. Chem. 271:15203-15210.
20. Jacobson, M.A., and T.R. Bai. 1997. The role of adenosine in asthma. In Purinergic Approaches in Experimental Therapeutics. K.A. Jacobson and M.F. Jarvis, editors. Wiley-Liss, Inc., Danvers, MA. 315-331.
21. Driver, A.G., C.A. Kukoly, S. Ali, and S.J. Mustafa. 1993. Adenosine in bronchoalveolar lavage fluid in asthma. Am. Rev. Respir. Dis. 148:91-97.
22. Cushley, M.J., A.E. Tattersfield, and S.T. Holgate. 1983. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br. J. Clin. Pharmacol. 15:161-165.
23. Walker, B.A., M.A. Jacobson, D.A. Knight, C.A. Salvatore, T. Weir, D. Zhou, and T.R. Bai. 1997. Adenosine A3 receptor expression and function in eosinophils. Am. J. Respir. Cell Mol. Biol. 16:531-537.
24. Barnes, P.J. 1997. Current therapies for asthma. Promise and limitations. Chest. 111:17S-26S.
25. Manquardt, D.L., C.W. Parker, and T.J. Sullivan. 1978. Potentiation of mast cell mediator release by adenosine. J. Immunol. 120:871-878.
26. Fozard, J.R., H.J. Pfannkuche, and H.J. Schuurman. 1996. Mast cell degranulation following adenosine A3 receptor activation in rats. Eur. J. Pharmacol. 298:293-297.
27. Knight, D., X. Zheng, C. Rocchini, M. Jacobson, I. Bai, and B. Walker. 1997. Adenosine A3 receptor stimulation inhibits migration of human eosinophils. J. Leukoc. Biol. 62: 465-468.
28. Ezeamuzie, C.I., and E. Philips. 1999. Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release. Br. J. Pharmacol. 127:188-194.
29. Kohno, Y., X. Ji, S.D. Mawhorter, M. Koshiba, and K.A. Jacobson. 1996. Activation of A3 adenosine receptors on human eosinophils elevates intracellular calcium. Blood. 88: 3569-3574.
30. Merrill, J.T., C. Shen, D. Schreibman, D. Coffey, O. Zakharenko, R. Fisher, R.G. Lahita, J. Salmon, and B.N. Cronstein. 1997. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum. 40:1308-1315.
31. Najar, H.M., S. Ruhl, A.C. Bru-Capdeville, and J.H. Peters. 1990. Adenosine and its derivatives control human monocyte differentiation into highly accessory cells versus macrophages. J. Leukoc. Biol. 47:429-439.
32. Eppell, B.A., A.M. Newell, and E.J. Brown. 1989. Adenosine receptors are expressed during differentiation of monocytes to macrophages in vitro. Implications for regulation of phagocytosis. J. Immunol. 143:4141-4145.
33. Revan, S., M.C. Montesinos, D. Naime, S. Landau, and B.N. Cronstein, 1996. Adenosine A2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. J. Biol. Chem. 271: 17114-17118.
34. Walker, B.A., C. Rocchini, R.H. Boone, S. Ip, and M.A. Jacobson. 1997. Adenosine A2a receptor activation delays apoptosis in human neutrophils. J. Immunol. 158:2926-2931.
35. Lee, J.J., M.P. McGarry. S.C. Farmer, K.L. Denzler, K.A. Larson, P.E. Carrigan, I.E. Brenneise, M.A. Horton, A. Haczku, E.W. Gelfand, et al. 1997. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J. Exp. Med. 185:2143-2156.
36. Escolar, J.D., B. Gallego, C. Tejero, and M.A. Escolar. 1994. Changes occurring with increasing age in the rat lung: morphometrical study. Anat. Rec. 239:287-296.
37. Knudsen, T.B., R.S. Winters, S.K. Otey, M.R. Blackburn, M.J. Airhart, J.K. Church, and R.G. Skalko. 1992. Effects of (R)-deoxycoformycin (pentostatin) on intrauterine nucleoside catabolism and embryo viability in the pregnant mouse. Teratology. 45:91-103.
38. Levy, Y., M.S. Hershfield, C. Fernandez-Mejia, S.H. Polmar, D. Scudiery, M. Berger, and R.U. Sorensen. 1988. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycolmodified adenosine deaminase. J. Pediatr. 113:312-317.
39. Shovlin, C.L., J.M. Hughes, H.A. Simmonds, L. Fairbanks, S. Deacock, R. Lechler, I. Roberts, and A.D. Webster. 1993. Adult presentation of adenosine deaminase deficiency. Lancet. 341:1471.
40. Hershfield, M.S., S. Chaffee, and R.U. Sorensen. 1993. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy. Pediatr. Res. 33:S42-S48.
41. Xu, P.A., J.H. Winston, S.K. Datta, and R.E. Kellems. 1999. Regulation of forestomach-specific expression of the murine adenosine deaminase gene. J. Biol. Chem. 274:10316-10323.
42. Weinstein, M., X. Xu, K. Ohyama, and C.X. Deng. 1998. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development. 125:3615-3623.
43. Bostrom, H., K. Willetts, M. Pekny, P. Leveen, P. Lindahl, H. Hedstrand, M. Pekna, M. Hellstrom, S. Gebre-Medhin, M. Schalling, et al. 1996. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell. 85:863-873.
44. Kaartinen, V., J.W. Voncken, C. Shuler, D. Warburton, D. Bu, N. Heisterkamp, and J. Groffen. 1995. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates detects of epithelial-mesenchymal interaction. Nat. Genet. 11:415-421.
45. Ray, P., W. Tang, P. Wang, R. Homer, C. Kuhn III, R.A. Flavell, and J.A. Elias. 1997. Regulated overexpression interleukin 11 in the lung. Use to dissociate development-dependent and -independent phenotypes. J. Clin. Invest. 100: 2501-2511.
46. Zhu, Z., R.J. Homer, Z. Wang, Q. Chen, G.P. Geba, J. Wang, Y. Zhang, and J.A. Elias. 1999. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103:779-788.
47. Strek, M.K., and A.R. Leff. 1997. Eosinophils. In Asthma, P.J. Barnes, A.R. Leff, M.M. Grunstein, and A.J. Woolcock, editors. Vol. 1. Lippincott-Raven, Philadelphia. 353-365.
48. Left, A.R. 1994. Inflammatory mediation of airway hyperresponsiveness by peripheral blood granulocytes. The case for the eosnophil. Chest. 106:1202-1208.
49. Gleich, G.J. 1990. The eosinophil and bronchial asthma: current understanding. J. Allergy Clin. Immunol. 85:422-136.
50. Johnson, H.G., and M.L. McNee. 1985. Adenosine-induced secretion in the canine trachea: modification by methylxanthines and adenosine derivatives. Br. J. Pharmacol. 86:63-67.
51. Hasko, G., C. Szabo, Z.H. Nemeth, V. Kvetan, S.M. Pastores, and E.S. Vizi. 1996. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 157:4634-4640.
52. Sajjadi, F.G., K. Takabayashi, A.C. Foster, R.C. Domingo, and G.S. Firestein. 1996. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J. Immunol. 156:3435-3442.
53. Salmon, J.E., N. Brogle, C. Brownlie, J.C. Edberg, R.P. Kimberly, H.X. Chen, and B.F. Erlanger. 1993. Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function. J. Immunol. 151:2775-2785.
54. Abboud, R.T., A.F. Ofulue, R.H. Sansores, and N.L. Muller. 1998. Relationship of alveolar macrophage plasminogen activator and elastase activities to lung function and CT evidence of emphysema. Chest. 113:1257-1263.
55. Bollinger, M.E., F.X. Arredondo-Vega, I. Santisteban, K. Schwarz, M.S. Hershfield, and H.M. Lederman. 1996. Hepatic dysfunction as a complication of adenosine deaminase deficiency. N. Engl. J. Med. 334:1367-1371.
56. Barnes, P.J., S.T. Holgate, L.A. Laitinen, and R. Pauwels. 1995. Asthma mechanisms, determinants of severity and treatment: the role of nedocromil sodium. Report of a workshop held in Whistler, British Columbia, Canada, 18-19 May 1995. Clin. Exp. Allergy. 25:771-787.